Literature DB >> 20427500

Growth hormone and health policy.

Leona Cuttler1, J B Silvers.   

Abstract

GH treatment for short children is representative of many frontline issues in health care policy. In this paper, we highlight key policy issues exemplified by GH, focusing on pharmaceutical innovation, insurance coverage and pricing, and physician decisions, and we discuss their implications for endocrinology and GH use.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20427500      PMCID： PMC2928896          DOI： 10.1210/jc.2009-2688

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  33 in total

1.  Variability and growth in spending for outpatient specialty pharmaceuticals.

Authors:  C Daniel Mullins; Andrea R DeVries; Van Doren Hsu; Fanlun Meng; Francis B Palumbo
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

2.  Lucrative niches: how drugs for rare diseases became lifeline for companies.

Authors:  Geeta Anand
Journal:  Wall St J (East Ed)       Date:  2005-11-15

Review 3.  Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature?

Authors:  Arlan L Rosenbloom
Journal:  Lancet       Date:  2006-08-12       Impact factor: 79.321

4.  Benefit design and specialty drug use.

Authors:  Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Prescription drug spending trends in the United States: looking beyond the turning point.

Authors:  Murray Aitken; Ernst R Berndt; David M Cutler
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

6.  Update on the State Children's Health Insurance Program.

Authors:  Leona Cuttler; Genevieve M Kenney
Journal:  Arch Pediatr Adolesc Med       Date:  2009-02

7.  Health spending projections through 2018: recession effects add uncertainty to the outlook.

Authors:  Andrea Sisko; Christopher Truffer; Sheila Smith; Sean Keehan; Jonathan Cylus; John A Poisal; M Kent Clemens; Joseph Lizonitz
Journal:  Health Aff (Millwood)       Date:  2009-02-24       Impact factor: 6.301

8.  Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.

Authors:  Rachel Brand
Journal:  State Legis       Date:  2008-09

9.  Short stature and growth hormone therapy. A national study of physician recommendation patterns.

Authors:  L Cuttler; J B Silvers; J Singh; U Marrero; B Finkelstein; G Tannin; D Neuhauser
Journal:  JAMA       Date:  1996-08-21       Impact factor: 56.272

10.  Current status of biosimilar growth hormone.

Authors:  Paul Saenger
Journal:  Int J Pediatr Endocrinol       Date:  2009-09-29
View more
  9 in total

1.  Biosimilar growth hormone.

Authors:  Paul Saenger
Journal:  Indian J Pediatr       Date:  2011-11-23       Impact factor: 1.967

2.  Idiopathic short stature: decision making in growth hormone use.

Authors:  Nidhi Maheshwari; Naveen K Uli; Sumana Narasimhan; Leona Cuttler
Journal:  Indian J Pediatr       Date:  2011-11-19       Impact factor: 1.967

Review 3.  Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today?

Authors:  Bharti Balhara; Madhusmita Misra; Lynne L Levitsky
Journal:  Indian J Pediatr       Date:  2011-11-17       Impact factor: 1.967

Review 4.  Clinical practice. Short stature in childhood--challenges and choices.

Authors:  David B Allen; Leona Cuttler
Journal:  N Engl J Med       Date:  2013-03-28       Impact factor: 91.245

5.  Effects of Early Initiation of Growth Hormone Therapy on Different Auxological Parameters in Growth Hormone Deficient Children: Experience from an Indian Tertiary Care Center.

Authors:  Inderpal S Kochar; Smita Ramachandran; Aashish Sethi
Journal:  Indian J Endocrinol Metab       Date:  2021-07-21

Review 6.  Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.

Authors:  Carlo L Acerini; David Segal; Sherwin Criseno; Kei Takasawa; Navid Nedjatian; Sebastian Röhrich; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

Review 7.  Effectiveness and Safety of Combination Therapy with Herbal Medicine and Growth Hormone Compared to Growth Hormone Monotherapy for Short Stature Children: A Systematic Review and Meta-Analysis.

Authors:  Soo Bo Shim; Hye Li Ahn; Hyun Hee Lee; Ju Ah Lee; Hye Lim Lee
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-09       Impact factor: 2.650

8.  Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument.

Authors:  Monika Bullinger; Julia Quitmann; Mick Power; Michael Herdman; Emmanuelle Mimoun; Kendra DeBusk; Eva Feigerlova; Carolina Lunde; Maria Dellenmark-Blom; Dolores Sanz; Anja Rohenkohl; Andreas Pleil; Hartmut Wollmann; John E Chaplin
Journal:  Health Qual Life Outcomes       Date:  2013-05-07       Impact factor: 3.186

9.  Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit.

Authors:  Juan F Sotos; Naomi J Tokar
Journal:  Int J Pediatr Endocrinol       Date:  2014-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.